(g) if so, what is the price approved and what is the present price at which it is being sold?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL) : (a), (d) and (e) Althrocin 500 mg Tablets is based on bulk drug Erythromycin Estolate and are produced by M/s. Alembic Chemical Works Co. Ltd. To the extent information is available a ceiling price of Rs. 47.82 was notified for 10's pack of this formulation on 22-5-1989.

(b), (c), (f) and (g) The required details will be collected and laid on the Table of the Rajya Sabha.

Prices of Oxyphenylbutazone Formulations

2363. DR. RATNAKAR PANDEY : Will the Minister of INDUSTRY be pleased to state :

(a) whether it is a fact that durg companies are over charging the prices of formulations based on Oxyphenylbutazone;

(b) whether it is also a fact that certain instances of overcharging have come to the Ministry's notice;

(c) if so, what are the details thereof ;

(d) whether it is also a fact that his Ministry has asked the leading formulators to provide the details of purchase of Oxyphenylbutazone and the rate of such purchase from April, 1979 onwards;

(e) if so, what are the names of the companies and when was such information asked from each;

(f) whether it is a fact that the companies are still overcharging the prices; and

(g) what was the price of Oxalgin fixed under DPCO, 1979 and what price is being charged at present for each pack and strength ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) Formulations based on Oxyphenylbutazone are not price controlled under DPCO, 1987.

(b), (c) and (f) Do not arise.

(d) and (e) Letters to some of the formulators were issued during 1984 calling for the details of procurement of the bulk drug in order to work out the liability arising under para 7 (2) of DPCO, 1979.

(g) Oxalgin is a combination of Oxyphenylbutazone with Analgin and is therefore price controlled under DPCO, 1987. To the extent information is available a price of Rs. 6.51 for 10's strip of Oxalgin tablets has been fixed on 7-7-1989. Details of price fixed under DPCO, 1979 from time to time are readily not available.

Production of Anti-leprosy Drugs

2364. SHRIMATI RATAN KUMARI :
SHRI SYED SIBETI RAZI :

Will the Minister of INDUSTRY be pleased to state :

(a) whether it is a fact that anti-leprosy and anti-T. B. drugs are being produced in the country;

(b) if so, what are the names of the drugs alongwith the name of the producer of each drug and the licensed capacity of each;

(c) what was the production of each such drug during the last three years, year-wise;

(d) what is the stage from which each drug is produced and what is the import contents per kg. of production in value;

(e) what was the price of each drug and its formulations under DPCO, 1979 and what is the price on 31st July, 1989 of each drug and its formulations;

(f) what was the mark up allowed under DPCO, 1979 and what is the present mark up; and

(g) what was the annual sales turn over of each drug in 1988 ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL) : (a) Yes, Sir.

(b) and (c) Details of licenses issued from time to time, such as names of companies and capacity licensed, are published regularly by India Investment Centre in their monthly newsletter, copies of which are available in the Parliament Library. Details of production of these drugs to the extent monitored, for the last three years, yearwise are given in enclosed Statement-I. (*See* below).

(d) Import content per Kg. of production is not monitored by this Ministry. However the licensed stages of manufacture are given in enclosed Statement-II (*See* below).

(e) and (f) Information asked for is too voluminous and time and labour involved in collection and compilation of data is not commensurate with the results likely to be achieved.

(g) Sales turnover of formulations is not monitored.

Statement-I

Name of drug/Company	A/C Unit	Production		
		1985-86	1986-87	1987-88
Anti-TB Drugs				
PAS & its Salts				
1. IDPL		38.85	26.35	32.45
2. Biochem Synth		47.65	42.2	15.77
3. Plizer		..	..	..
4. Wander		20.48	17.78	20.55
5. Bio-Evans		..	..	..
Thiacetazone				
1. Bio-Evans		..	..	..
2. Uhichem Labs.		19.23	28.93	39.58
Isoniazid				
1. Chemo Pharma		71.69	82.16	0.35
2. Plizer		71.74	97.82	44

3. Suneeta Labs	..	..	..
4. Bio Evans	0.91	..	..
5. Jain Kaliawala	..	8.6	13.49
Ethambutol			
1. Themis Chemicals	30.43	22.15	..
2. Cadila Lab.	30.41	19.59	21.56
3. Lyphin Chemical	11.04	13.12	13.55
4. Lupin Labs.	221.92	243.90	319.14
5. Raptakos Brett	0.10	1.08	0.05
6. Sarabhai Chemical	..	0.01	0.01
7. Jain Kaliawala	1.95	..	..
8. Wockhardt Ltd.	4.87	..	..
Pyrazinamide			
1. Standard Organics	..	..	1.36
2. Uni-Sankyo	1.86	1.44	2.28
3. Indo Pharma	1.24	1.37	1.24
4. Morani Chemicals	0.11	..	..
Anti-Peprotics Dapsone			
1. BCPL	0.7	..	0.45
2. Burroughs Wellcome	6.73	21.3	15.41
3. Tuber Pharma	0.50	0.83	7.68
4. CIPLA	..	3.37	..
Clofazimine			
1. Astra-IDL	1.19	0.39	1.67
2. S.G. Chemicals	1.31	0.27	0.40

Statement-II

Name of drug	Licensed stage of manufacture
1. PAS & its Salts	Basic stage
2. Thiacetazone	Basic stage
3. Isoniazid	Basic Stage
4. Ethambutol	Intermediate
5. Pyrazinamide	Basic/Intermediate
6. Dapsone	Basic
7. Clofazimine	Intermediate